Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (RAMP205)

Inclusion Criteria: Male or female subjects ≥ 18 years of age Histologic or cytologic evidence of metastatic pancreatic ductal adenocarcinoma. An Eastern Cooperative Group (ECOG) performance status ≤ 1 Measurable disease according to RECIST 1.1 Adequate organ function Adequate cardiac function Agreement to use highly effective method of contraceptive Exclusion Criteria: Patients with pancreatic neuroendocrine tumors Prior or concomitant treatment for metastatic pancreatic ductal adenocarcinoma Prior treatment with inhibitors of the RAS /MAPK pathway [e.g. MEK inhibitors] or inhibitors of FAK History of prior malignancy, with the exception of curatively treated malignancies Major surgery within 4 weeks (excluding placement of vascular access) Concurrent heart disease or severe obstructive pulmonary disease Concurrent ocular disorders Active skin disorder that has required systemic therapy within the past 1 year Patients with interstitial lung disease or pulmonary fibrosis or severe lung disease, pulmonary edema, and adult respiratory distress syndrome Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy